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Abstract
The aim of this paper is to analyze why ozone can be medically useful when it dissolves in blood or in other
biological fluids. In reviewing a number of clinical studies performed in Peripheral Arterial Diseases (PAD) during
the last decades, it has been possible to confirm the long-held view that the inverted U-shaped curve, typical of
the hormesis concept, is suitable to represent the therapeutic activity exerted by the so-called ozonated
autohemotherapy. The quantitative and qualitative aspects of human blood ozonation have been also critically
reviewed in regard to the biological, therapeutic and safety of ozone. It is hoped that this gas, although toxic for
the pulmonary system during prolonged inhalation, will be soon recognized as a useful agent in oxidative-stress
related diseases, joining other medical gases recently thought to be of therapeutic importance. Finally, the
elucidation of the mechanisms of action of ozone as well as the obtained results in PAD may encourage clinical
scientists to evaluate ozone therapy in vascular diseases in comparison to the current therapies.
Introduction
Ozone is a double-faceted gas. It has a crucial protective
relevance in partially blocking mutagenic and carcino-
genic UV radiations emitted by the sun (wavelengths of
100-280 nm) in the stratosphere [1], while its increasing
concentration in the troposphere causes severe pulmon-
ary damage and increased mortality [2,3]. In spite of this
drawback, there are growing experimental and clinical
evidences about the medical use of ozone [4-11]. Since
XVI Century, Paracelsus had ingeniously guessed that
“all things are poison and nothing is without poison and
only the right dose differentiates a poison from a
remedy”. In 2005, Timbrell reiterated the concept in his
book: “The poison paradox; chemicals as friends and
foes” [12]. During the Earth evolution, harnessing oxy-
gen by metazoans has allowed a fantastic biodiversity
and growth but it has also created a slow acting “poi-
son”. It is reasonable to believe that the antioxidant sys-
tem slowly evolved and specialized during the last two
billion years for counteracting the daily formation (3-5 g
in humans) of anion superoxide in the mitochondria
and the release of H2O2 by ubiquitous NADPH oxi-
dases. However, there is a general consensus that the
physiological production of H2O2 is essential for life.
Olivieri et al. [13] and Wolff [14] were the first to
describe the effect of either low concentrations of radio-
active thymidine or of a very low dose of radiation indu-
cing an adaptive response in human cells in comparison
to a high dose. Goldman [15] introduced the term
“hormesis” to mean “the beneficial effect of a low level
exposure to an agent that is harmful at high levels”.I t
goes to the merit of Calabrese [16-19] to have experi-
mentally controlled this concept and to have presented
a number of examples of stimulatory responses follow-
ing stimuli below the toxicological threshold. Until 2002
ozone therapy was pharmacologically conceived as a
therapy where low ozone doses were stimulatory, while
high doses were inhibitory. This conception, reflecting
the classical idea that a low antigen dose is stimulatory,
where an antigen overdose is inhibitory, was vague and
unsuitable because ozone acts in a complex way and a
high dose can still be effective but accompanied by side-
effects. Indeed, one of us in 2002 amply delineated the
sequence of biochemical reactions elicited ex vivo after
the addition of a certain volume of O2-O3 gas mixture
to an equal volume of human blood [20]. First of all,
mixing blood with an oxidant implies a calculated and
precise oxidative stress, i.e. a homeostatic change with
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stress, like many others, induces a biological response
leading to an adaptive phenomenon. The teleological
significance of this response is universal, from bacteria
to plants and Mammals, and small repetitive stresses
induce an extremely useful adaption response repre-
sented by the revival of critical defense mechanisms
[20-22]. At the same time, Calabrese and Baldwin
described the “overcompensation stimulation hormesis”
(OCSH) as the result of a compensatory biological pro-
cess following an initial disruption in homeostasis [17].
After a reviewer’s information also Re later on had
expressed this possibility [23]. Ozone presents some
subtle differences that will be explained by clarifying the
biochemical reactions occurring between the organic
compounds of plasma and this gas.
Ozone is a Strong Oxidant Gas
The three oxygen atoms in gas-phase ozone form an
isosceles triangle with a distance among the equal sides
of 1.26 Å, and exist in several mesomeric states in
dynamic equilibrium [24]. In terms of oxidation poten-
tial (E°), ozone (2.07 V) is the third after fluorine (3.06
V) and hydroxyl radical (2.80 V). Other pertinent oxi-
dants are: hydrogen peroxide (1.77 V), hypochlorous
acid (1.49 V) and chlorine (1.36 V). Ozone has a paired
number of electrons in the external orbit and, although
it is not a radical molecule, it is far more reactive than
oxygen and readily generates some of the ROS produced
by oxygen. Ozone is very unstable and at 20 °C, with a
half-life of about 40 min, it decomposes according to
the exothermic reaction:
3O2 + 68,400  2O3
Such an aspect has generated the idea that ozone will
donate its energy to the organism by reacting with specific
body compartments [20]. However, after having ascer-
tained the complexity of the mechanism of action, the
conclusion is that ozone dissolved in the water of plasma
acts as a pro-drug, generating chemical messengers which
will accelerate transfer of electrons and the overall meta-
bolism. It goes to the merit of Hans Wolff (1927-1980), a
German physician, to have developed the O3-AHT by
insufflating ex vivo a gas mixture composed of medical
oxygen (95%) and ozone (5%) into the blood contained in
a dispensable ozone-resistant and sterile glass bottle [25].
Which are the Blood Components Reacting with
Ozone?
For almost three decades ozone therapy was used only
in Germany by practitioners who, by using empirical
procedures, elicited skepticism and prejudice in aca-
demic clinical scientists. Only during the last fifteen
years, by using modern ozone generators able to
photometrically (253.7 nm) measure the ozone concen-
tration in a specified gas volume, in real time, and in a
precise manner (hence the precise ozone dose per ml of
blood), it has been possible to accurately study the reac-
tions of ozone with human blood. It has been clarified
that ozone toxicity depends upon its dose and, more
important, that judicious ozone dosages can be neutra-
lized by biological defenses [4,20-22,26]. Blood contains
some 55% of plasma and about 45% of cells, the bulk of
which is represented by erythrocytes. The composition
of plasma is complex but, simply said, it contains: about
92% of water; dissolved ions such as HCO3
- and PO4
3-
regulate the pH within the range of 7.3-7.4; both hydro-
philic (glucose, uric acid, ascorbic acid, cysteine and
other amino acids) and lipophilic (bilirubin, vitamin E,
carotenoids, lycopene) molecules; about 5 mg lipids (tri-
glycerides, cholesterol, phospholipids and lipoproteins);
proteins, among which albumin (4.5 g/dl), fibrinogen as
well as globulins, among which either transferrin or cer-
uloplasmin binds either Fe
2+ or Cu
+, respectively, coagu-
lation factors and hormones. Among the plasma main
functions, one is the antioxidant activity performed by a
variety of molecules such as uric acid (4.0-7.0 mg/dl,
400 μM), ascorbic acid (Aa) (0.4 - 1.5 mg/dl, 22,7-85 µ;
M), GSH (0.5-1.0 μM), the mentioned lipophilic com-
pounds as well as albumin. In detail, erythrocytes have a
great reservoir of GSH (about 1 mmol/l), thioredoxin
with two available cysteine, and potent antioxidant
enzymes (catalase, GSH-Rd, GSH-Px, GSH-Tr, and
SOD). They can quickly wipe out great amounts of oxi-
dants such as
·OH, H2O2,O C l
-,O N O O
- and, at the
same time, recycle protons back to oxidised compounds
by using protons donated by NADPH continuously
regenerated by the activity of G6PD via the pentose
phosphate pathway. It must be noted that most of these
antioxidants work in concert accelerating the reduction
of noxious oxidants (Figure 1). Albumin on its own is
the most important because it holds nucleophilic resi-
dues, such as one free Cys34 as well as multiple Lys199
and His146 [27,28].
The Biochemical Reactions of Ozone with Blood
During the most precise and safe methodological ex vivo
O3-AHT approach, oxygen-ozone mixture dissolves into
the water of plasma. Oxygen has a low solubility, but
the pO2 slowly raises up to about 400 mmHg [29].
Hemoglobin become fully oxygenated (Hb4O8)b u tt h i s
is hardly relevant because, during the infusion period, it
mixes with venous blood which has a pO2 of about 40
mmHg. On the other hand, ozone behaves quite differ-
ently because, by immediately reacting with ions and
biomolecules, it does not follow the classical Henry’s
law in terms of linear solubility variation with pressure.
First of all ozone is about tenfold more soluble than
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instantaneously reacts with hydrophilic antioxidants: by
using an ozone concentration of 40 μg/ml, correspond-
ing to 0.84 µ;mol/ml per ml of blood, within five min an
average of 78% of Aa has been oxidized to dehydroas-
corbate and about 20% of uric acid has been oxidized to
allantoin [30]. Only about 10% of alpha tocopherol has
formed an alpha tocopheryl radical. At the same time the
remaining ozone performs the peroxidation of available
unsaturated fatty acids, which represent an elective sub-
strate and are mostly albumin-bound. Peroxidation of n-
6 PUFA leads to the formation of H2O2 and 4-hydroxy-
2E-nonenal (4-HNE) [31], while n-3 PUFA leads to the
formation of 4-hydroxy-2E-hexenal (4-HHE) [32,33]:
-R-CH=CH − R+H 2O + O3  2RHCO +H 2O2
As all of these reactions happen in a few seconds,
ozone, until present in the gas phase, continues to dis-
solve in the plasmatic water and instantly reacts. Within
the canonical 5 min, ozone is fully extinct with both a
rather small depletion of hydrosoluble antioxidants and
the simultaneous plasmatic increase of ROS and LOP.
The ozonated blood is then infused into the donor
patient.
What is the Significance and Fate of These Ozone
Messengers?
First of all the brief life-span of H2O2 will be discussed.
During the 5 min of mixing blood with the gas ex vivo,
H2O2 will dynamically increase its concentration: rapid
at first and progressively slowing down as ozone is
being depleted. With the therapeutically high ozone
concentration of 80 μg/ml per ml blood, the H2O2 con-
centration measured in plasma after 2.5 min is at most
40 μM because the rate of synthesis is equilibrated by
multiple degradation routes. Some H2O2 is reduced by
free soluble antioxidants including traces of catalase and
GSH-Px. As the hemolysis is negligible (<0.5%), free Fe
2
+ or Cu
+ are not present and it is unlikely that hydroxyl
ions are ever formed by either the Fenton-Jackson or
the Haber-Weiss reactions. As H2O2 is unionized, it
freely diffuse into all blood cells although the bulk is
mopped up by erythrocytes. The establishment of a
dynamic, yet transitory, H2O2 gradient between the
plasma and the cytoplasmatic water of blood cells
makes this oxidant a very early effector. Its final intra-
cellular concentration may be not higher than 10%,
hence 3-4 μmoles, as it has been demonstrated in other
studies [34-39]. The smartness of this system is that the
H2O2 concentration, though small, is enough to trigger
several crucial biochemical reactions without toxicity
because the internal cell environment contains a wealth
of GSH, thioredoxin, catalase and GSH-Px, which do
not allow a dangerous increase. In spite of a threshold
of only a few micromoles, it has a critical relevance and
means that an ozone amount below 0.42 μmol for each
ml volume of the gas mixture (medical grade O2 ≥95%
and O3 ≤5%) reacting in a 1:1 ratio with autologous
blood may be ineffective, resulting in a therapeutic fail-
ure of O3-AHT. It is also necessary to remind that the
ozonation process greatly differs whether it occurs either
in plasma or in blood. In plasma, TAS levels was, as
expected, ozone-dose dependent and decreased between
46 and 63% in relation to ozone concentrations of either
0.84 μmol/ml or 1.68 μmol/ml per ml of plasma, respec-
tively. On the other hand, in blood taken from the same
donors, after being treated with the same ozone concen-
trations, TAS only decreased from 11 to 33% in the first
minute after ozonation, respectively. Moreover, it was
surprising to determine that they both recovered and
returned to the original value within 20 min, indicating
the capacity of blood cells to quickly regenerate dehy-
droascorbate and GSH disulfide [34]. It has been also
brilliantly demonstrated that, thanks to erythrocytes,
dehydroascorbate was recycled back to Aa within 3 min
[40]. On the same way, only about 20% of the intraery-
throcytic GSH had been oxidized to GSSG within one
min after ozonation and promptly reduced to normal
after 20 min [41]. Aa, alpha-tocopherol, GSH and lipoic
acid undergo an orderly reduction by a cooperative
Figure 1 Cellular responses to oxidant exposure. ROOH and ROO￿ indicate lipohydroperoxide and its oxygen centered organic radicals
formed by radical reactions with cellular components, respectively. GSH and GSSG represent the sulfhydryl/disulfide pair of glutathione species.
Nicotinamide adenine dinucleotide phosphate, NADP(H), is the primary electron source, regenerated by the cellular reduction systems.
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NADPH-reducing equivalents to GSH-Rd and thiore-
doxin reductase [42] (Figure 1). These data, by showing
that the therapeutic ozonation only temporarily and
reversibly modifies the cellular redox homeostasis were
reassuring regarding the safety of ozone as a medical
drug. In summary, the initial disruption of homeostasis
due to ozone oxidation is followed by the rapid reestab-
lishment of homeostasis with two main advantages: the
first being the value of triggering several biochemical
reactions in blood cells and the second mediated by
LOP compounds, the induction of an adaptive process
due to the up-regulation of the antioxidant enzymes.
This is in line with the temporal sequence of the OCSH
dose-response relationship.
What is the Action of Ozone in the Blood Cells?
- Erythrocytes
Probably the activation of phosphofructokinase acceler-
ates glycolysis with a demonstrated increase of ATP and
2,3-DPG [4,20]. Functionally, the oxyhemoglobin sigmoid
curve shifts to the right owing to the Bohr effect, i.e. a
small pH reduction (about 7.25) and a slight increase of
2,3-DPG. This metabolite increases only in patients who
have a very low level but it remains to be clarified how
the phosphoglyceromutase is activated. The shift to the
right is advantageous for improving tissue oxygenation as
the chemical bonding of oxygen to hemoglobin is attenu-
ated, facilitating oxygen extraction from ischemic tissues.
Rokitansky et al., had previously shown that the pO2 was
lowered to 20-25 mm Hg in the femoral vein of PAD’s
patient throughout O3-AHT sessions [43]. It seems
obvious that erythrocytes ozonated ex vivo may be modi-
fied only for a brief period. Only repeated therapeutic
sessions may allow to LOP compounds to reach the
bone-marrow and activate a subtle development at the
erythropoietic level, favouring the formation of new ery-
throcytes with improved biochemical characteristics,
which provisionally were named “supergifted erythro-
cytes” [20]. If this hypothesis is correct, every day, during
prolonged ozonetherapy, the bone marrow may release a
cohort (about 0.9% of the pool) of new erythrocytes with
improved biochemical characteristics. In fact, the thera-
peutic advantage does not abruptly stop with the cessa-
tion of the therapy but rather persists for 2-3 months,
probably in relation to the life-span of the circulating
supergifted erythrocytes [26]. It is interesting that during
prolonged ozonetherapy, by isolating through a sedimen-
tation gradient the small portion of very young erythro-
cytes, it has been demonstrated that they have a
significant higher content of G6PD [44]. Such a result
strengthens the postulation that only a cycle of more
than 15 treatments (not less than 3 liters of ozonated
blood) could improve an ischemic pathology.
- Leukocytes
Human neutrophils are able to generate an ozone-like
molecule [45] and volatile compounds [46] as a part of
their phagocyte activity. Neutrophil phagocytic activity
has been found enhanced during ozonetherapy [47].
Moreover, H2O2 activates a tyrosin-kinase with subse-
quent phosphorylation of IkB, one of the trimeric com-
ponents at rest of the ubiquitous transcription factor
denominated NF-kB [48,49]. The phosphorylated IkB
detaches from the trimer and it is broken down in the
proteasome. The remaining eterodimer p50-p65 is trans-
ferred into the nucleus, where it can activate about 100
genes up-regulating the synthesis of acute-phase pro-
teins, several proinflammatory cytokines (IFN-g,T N F - a,
I L - 8 )a n de v e nH I Vp r o t e i n s[ 5 0 ] .T h e r ei sn od o u b t
that H2O2 is the trigger as the activation is related to a
cysteine oxidation that can be prevented by an excess of
thiol. Although ozone is a very modest inducer of some
cytokines [50], the consequent immunomodulatory
effect may be useful in immune-depressed patients after
chemotherapy, or in chronic infectious diseases. It must
be clear that ozone in itself cannot exist in the circula-
tion and moreover, due to the potent antioxidant capa-
city of plasma, it is unable to kill any pathogens in vivo
whereas an activated immune system may be helpful
[51].
- Platelets
During O3-AHT, the detection of PDGF-B, TGF-b1,I L -
8 and EGF released in heparinized plasma in ozone-
dose dependent quantities was not surprising because
platelets are exquisitely sensitive to a progressive acute
oxidative stress [20,52]. The increased level of these
growth factors in the circulation may have the beneficial
effect of enhancing the healing of foot-related problems
from diabetes or PAD.
The pleiotropic LOP activities
As shown in Figure 2, LOP production follows peroxida-
tion of PUFA present in the plasma: they are heteroge-
neous and can be classified as lipoperoxide radicals,
alkoxyl radicals, lipohydroperoxides, F2-isoprostanes, as
well as aldehydes like acrolein, MDA and terminal
hydroxyl alkenals, among which 4-HNE and 4-HHE. As
free radicals and aldehydes are intrinsically deleterious,
only precise and appropriate ozone doses must be used
in order to generate them in very low concentrations.
Among the aldehydes, 4-HNE is quantitatively the most
important. It is an amphipathic molecule and it has a
brief-half-life in saline solution. On the other hand it
reacts with a variety of compounds such as albumin,
enzymes, GSH, carnosine, and phospholipids [31,53].
There is no receptor for 4-HNE but it has been reported
that, in concentration above 1 μM in vitro, after binding
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deleterious activity [31]. On the other hand, during the
rapid reaction of ozone with blood, the generated
hydroxy-alkenals, will form adducts both with GSH or
with the abundant albumin molecules. This possibility is
supported by findings which have shown that human
albumin, rich in accessible nucleophilic residues, can
quench up to nine 4-HNE molecules, the first being
Cys34, followed by Lys199 and His146 [27,28]. Interest-
ingly, when samples of ozonated human plasma were
incubated at 37 °C for 9 hours, 4-HNE, most likely
bound to albumin, remained stable [54]. These data
clarify why a judicious ex vivo ozonation of blood does
not harm the vascular system during the infusion into
the donor. Aerobic organisms, in order to tolerate the
continuous generation of aldehydic compounds have
developed detoxifying systems as follows: the first is the
dilution of these products in both the plasma and the
extracellular fluid involving a volume of about 11 L in
humans. The second is the detoxification operated by
aldehyde dehydrogenase, aldose reductase and GSH-Tr
[55,56] and the third is the excretion via bile and urine
excretion [57-59]. The relevance of these catabolic path-
ways was appreciated when the half-life of infused alke-
nals present in ozonated blood in a patient was less
than 5 min [60]. The interesting aspect is that albumin
can transport 4-HNE in all body tissues, from liver to
endocrine glands and the CNS. 4-HNE-Cys adducts,
released at many sites, inform a variety of cells of a tran-
sient, acute oxidative stress and represent an important
biochemical trigger. At submicromolar or picomolar
levels, 4-HNE can act as a signaling molecule capable of
activating the synthesis of g-glutamate cysteine ligase, g
-glutamyl transferase, g -glutamyl transpeptidase, HSP-
70, HO-1, and antioxidant enzymes such as SOD, GSH-
Px, catalase and last but not least, G6PDH, a critical
electron-donor enzyme during erythropoiesis in the
bone marrow. There is a wide consensus on the rele-
vance of the induction of protective molecules during
small but repeated oxidative stress [20,61-65]. In other
words, the concept that a precisely controlled oxidative
stress can strengthen the antioxidant defenses is well
accepted today. Once again, the low level of stress by
enhancing the fitness of the defense system, is consistent
with the hormetic concept. Moreover at the time of
ozonated blood infusion, 4-HNE-Cys adduct can also
act on the vast expanse of endothelial cells and enhance
the production of NO [35]. Such a crucial mediator on
its own or as a nitrosothiol, with a trace of CO released
with bilirubin via HO-1 activity, allows vasodilation,
thus improving tissue oxygenation in ischemic tissues
[66]. H2S is another potentially toxic molecule that,
Figure 2 Generic scheme of polyunsaturated fatty acids peroxidation. Arachidonic acid reactions have been detailed, but similar pathways
are applicable to other polyenoic fatty acids. MDA: malondialdehyde. HHE: 4-hydroxy-2E-hexenal. HNE: 4-hydroxy-2E-nonenal.
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tant physiological vasodilator like NO and CO [67,68].
Moreover, as it happens for the mentioned physiological
traces of other gases, the small amount of ozone neces-
sary to trigger useful biological effects is in line with the
concept of the hormesis theory [69].
Another interesting aspect observed in about 2/3 of
patients is a sense of wellness and physical energy
throughout the ozonetherapy [70]. It is not yet known
whether these feelings are due to the power of the gen-
erated ozone messengers which can modify or improve
the hormonal secretion. On the other hand, the feeling
of euphoria may be due to improved oxygenation or/
and enhanced secretion of growth hormone, ACTH-cor-
tisol and dehydroepiandrosterone [26,71]. Furthermore,
when LOP reach the hypothalamic area they may
improve the release of serotonin and endorphins, as it
was observed after intense dynamic exercise [72].
Experience acquired after thousands O3-AHT has clari-
fied that there is neither objective nor subjective toxi-
city, or to use Calabrese’s acronyms, there is no
observable adverse effects (NOAEL). Moreover, neither
structural nor enzymatic damages have been observed in
blood components after ozonation of blood within the
therapeutic window [73,74]. On the other hand, patients
with more advanced disease during the initial session
especially if performed with a high ozone dosage, fre-
quently report to feel very tired and sleepy. This is the
lowest observed adverse effect level (LOAEL) that has
been observed in about 10% of PAD’sp a t i e n t sw i t h
stage III and IV of the Leriche-Fontaine’s classification.
Such a knowledge compels to begin always with low
ozone dosage and carefully observe the patient’s
response.
Which is the Most Suitable Term for Describing
the Dose-Response Relationship Between Ozone
and Blood?
O z o n ei sat o x i cg a sa n di tc a n n o tb ec o m p a r e dt o
either any usual immunological stimulus or to stable
chemical compounds: firstly, nobody has ever described
a cell receptor for ozone, and secondly the biochemical
reactions with blood components generate various mes-
sengers with quite different half-lives, finalities and fate.
Moreover, not only biological but also clinical responses
have to be taken into account when using ozonetherapy
in quite different pathologies such as cardiovascular, or
autoimmune or orthopedic diseases. The hormetic dose
response appears to be useful for describing the dual
pharmacological response elicited by ozone, basically
acting as a pro-drug. The most common form of the
hormetic dose response curve, depicting low dose stimu-
latory and high dose inhibitory and toxic responses is
the ß- or inverted U-shaped curve shown in Figure 3,
panel a. However, the graphic illustration of the hor-
metic dose-response relationship between ozone and
blood needs an explanation because it slightly differs
from graphs presented on the effect of other stressors
(Figure 3, panel b) [26,75-78]. It has been found that an
ozone dose of only 10 µ;g/ml (0.21 μmol/ml) per ml of
blood is fully neutralized by both uric acid and Aa, espe-
cially when the TAS of individual blood is between 1.5-
1.9 mM [79]. It follows that the minimal reaction, if
any, with PUFA will not generate enough messengers as
Figure 3 The hypothetical inverted U-shaped curve describing an ideal dose-response relationship (panel A). The inverted U-shaped
curve drawn on the basis of the therapeutic effect in PAD’s patients by using an ozone concentration range between 15 and 80 μg/ml of gas
per ml of blood. During a course of 15-20 sessions, the initial ozone concentration of 10 μg/ml has been slowly upgraded to the concentration
of 80 μg/ml (panel B). The end-points that have been considered to determine the therapeutic effects are: claudication; ankle-brachial index;
disappearance of pain; healing of skin ulcers.
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the small ozone dose is totally consumed by available
free antioxidants and the ozonated blood will not dis-
play therapeutic activity. Gaseous ozone doses between
20 and 80 µ;g/ml (0.42-1.68 μmol/ml) per ml of blood
are well calibrated against blood’s TAS and both biologi-
cal and therapeutic effects will ensue. A recent metabo-
nomic study has shown that the blood antioxidant
capacity is almost exhausted when the ozone dose has
been raised to 160 µ;g/ml per ml of blood [74]. In sim-
ple words, too little ozone, unable to modify the homeo-
static equilibrium, is unable to elicit the hormetic
response. On the basis of the last observation, it would
be most interesting to analyze the response in normal
volunteers.
Ozone Therapy in Oxidative-Stress Related
Diseases
The metabolic syndrome is recognized as one of the
most serious disease in Western countries caused by a
number of metabolic alterations such as type-2 diabetes,
hypercholesterolaemia, atherosclerosis and renal dys-
function with the common denominator represented by
a chronic oxidative stress. Diabetic patients, particularly
those with foot ulcers, are critical and today they still
have a gloomy prognosis. This is because they need a
multiform therapy aiming to eliminate the peripheral
ischemia, the neuropathy and the infected skin lesions.
The range of ozone concentrations between 15 and 35-
50 µ;g/ml is safe also in individuals with a low TAS
level and it appears to be particularly effective in PAD
[43,80-85]. Several clinical studies performed in different
hospitals seem to establish the validity of the inverted
U-shaped curve in this frequent pathology (Figure 3,
panel B). In line with “the concept of a beneficial effect
within the context of a dose-response study is difficult
to determine due to considerable biological complexity
and the fact that beneficial effects are often seen with
reference to a specific and relative setting” [17], a word
of caution is necessary. This is especially true when
ozone therapy is performed in different patients within
the variety of three PAD’s II, III and IV stages, accord-
ing to the Leriche-Fontaine classification [86]. First of
all it is necessary to trust the precision of ozone’s
dosages used by different clinicians and secondly, ozone
activity cannot be compared with that expressed by a
single compound (see, eg, Arsenic [76], and homocys-
teine [77]) in cultured cells. As it has been clarified, the
real ozone messengers are H2O2 as a ROS and a variety
of alkenals as LOP. These messengers act on different
cells, have a quite different lifetime and alkenals are
intrinsically toxic. Furthermore, each patient has his
own medical history and his own psycho-physical reac-
tivity. Consequently, ozone dosages between 0.42-0.84 µ;
mol/ml generate less alkenals than dosages in the range
0.84-1.68 µ;mol/ml, and therefore patients with a low
antioxidant capacity become more susceptible to a side
effect like deep fatigue after the therapy session. Atten-
tion must be also paid to the type of pharmacological
response achieved in different pathologies as either mus-
cular-orthopedic or autoimmune diseases. So far, in the
latter it remains unknown the ozone dosage, if any, able
to increase the T-cell regulatory levels and activity. Con-
sequently, at this stage the U-shaped curve remains
meaningful only for PAD and only future trials will be
able to define the ozone behavior in either stroke or
chronic heart disease. Martinez-Sanchez et al. have also
reported that the theoretical U-shaped curve fits the
ozone therapy results [87]. Blood ozonation, even if per-
formed within the therapeutic range and for a few min-
utes, represents always a calibrated acute oxidative
stress. In order to never harm the patient, the strategy:
“start low-go slow” i sag o l d e nr u l et oi n d u c eav a l i d
adaptation to the far more dangerous chronic oxidative
stress, typical of inflammatory and degenerative diseases
[88]. Such an aspect implies that the final therapeutic
effect is due to an average of progressively increasing
ozone dosages.
The gas mixture medical grade oxygen-ozone can be
proficiently used for the ozonation of blood because this
incomparable liquid tissue contains an imposing array of
antioxidants, which are able to tame not only its oxidant
power but also its messengers (ROS and LOP) generated
by the reactions with blood components. Therefore, if
ozone is judiciously used within the established thera-
peutic window (0.42-1.68 μmol/ml per ml of autologous
blood) in PAD, it can exert better therapeutic effects
than the current therapy by prostacyclin analogue.
Moreover, regarding the accompanying foot-related pro-
blems, both some ozone derivatives like ozonated water
and different gradation of standardized ozonated vegeta-
ble oils will be used until complete healing [89,90]. As
stroke, heart infarction and PAD are cumulatively the
first cause of death and disability, if it will become pos-
sible to use ozone therapy in the public hospitals of the
developed Countries, it may be possible to enter a phase
where ozone will become an extensive remedy. More-
over, there is no doubt that either infective or autoim-
mune glomerulo-nephritis as well as end stages of renal
failure associated with hemodialysis are characterized, to
a different extent, by an imbalance between pro- and
antioxidative mechanisms [91]. Moreover the kidney
does not have the regenerative ability of liver and this is
one of the reasons for explaining why too often
“nephropaties lack a specific treatment and progress
relentlessly to end-stage renal disease” [92]. Another
important reason is that till today a valid strategy to
reduce oxidative stress in renal diseases is not available.
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stress, but it may also stimulate untapped resources able
to afford some improvement [9,93]. It appears therefore
reasonable to suggest the combination of conventional
treatments with mild O3-AHT in any initial nephropa-
thy for preventing the risk of progression towards a
chronic disease.
In several Countries, among others Cuba, Russia, and
Ukraine, treatments by ozone are already a reality,
although different administration modalities, such as the
infusion of ozonated saline and of the rectal insufflations
of ozone, are in current use because inexpensive and
applicable to thousands of patients every day [94].
Nevertheless, it is hoped that adequate ozone-based
therapeutic treatments for patients affected by oxidative-
stress related diseases could be implemented in every
public hospital.
Conclusions
During the last two decades the paradoxical behaviour
of ozone has been clarified: when it is chronically
inhaled, it is highly toxic for the pulmonary system
because the enormous alveolar surface, unprotected by
sufficient antioxidants, is exposed to the cumulative
ozone dose, which causes a chronic inflammation. This
is not surprising because even for oxygen [95], as well
as for glucose and uric acid levels a modification of the
physiological concentrations is deleterious.
On the basis of the mechanisms of action, ozone ther-
apy appears to be a safe, economical, effective treatment
for patients with cardiovascular disorders based on the
following biological responses [26]:
a) it improves blood circulation and oxygen delivery to
ischemic tissue owing to the concerted effect of NO and
CO and an increase of intraerythrocytic 2,3-DPG level;
b) by improving oxygen delivery, it enhances the gen-
eral metabolism;
c) it upregulates the cellular antioxidant enzymes and
induces HO-1 and HSP-70;
d) it induces a mild activation of the immune system
and enhances the release of growth factors from
platelets;
e) it procures a surprising wellness in most of the
patients, probably by stimulating the neuro-endocrine
system. However, ozone dosages must be calibrated
against the antioxidant capacity of the patient’sp l a s m a ,
or otherwise the “start low-go slow” strategy must be
used evaluating the subjective feeling of the patient after
each session.
It remains to be clarified whether some messengers
present in the ozonated blood are able to stimulate the
release of staminal cells in the patient’s bone marrow.
The evaluation of results obtained in several clinical
trials performed in PAD has allowed to establish that
the dose-response relationship in PAD can be depicted
as an inverted U-shaped hormetic model with a brief,
initial lack of effect due to the potency of blood anti-
oxidants. A mild acute oxidative stress induced by
ozone in blood ex vivo, as several other mild stresses
due to either heat or cold exposure, a transient ische-
mia, other chemicals and physical exercise are able to
induce a sort of “preconditioning response” often lead-
ing to both a repair and an increased defense capacity
well within the “overcompensation stimulation horm-
esis”. This new achievement, added to an increasing
wide consensus in carefully using gases as NO, CO,
H2S, N2Oa n dH 2 as real medical drugs [68], suggests
that also ozone may be soon included into this cate-
gory. One of the basic functions of ozone, after dissol-
ving in the water of plasma is to accelerate the
exchange of protons and electrons or, in simple
words, to reactivate the metabolism all over the body.
In this way, crucial biological functions gone astray
can recover indicating that ozone operated as both a
biological response modifier and an antioxidant
inducer.
It is hoped that this paper will elicit the interest of
clinical scientists in evaluating ozone therapy in vascu-
lar, renal and diabetic diseases, thus translating the
laboratory results to the patient’s bed.
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